ストックスクリーナーアプリを入手
2.98
0.67%
-0.02
プレマーケット:
2.89
-0.09
-3.02%
前日終値:
$3.00
開ける：
$3
24時間の取引高:
173.46K
Relative Volume:
0.48
時価総額：
$141.89M
収益：
$230.47M
当期純損益:
$30.28M
株価収益率:
4.8852
EPS:
0.61
ネットキャッシュフロー:
$38.86M
1週間 パフォーマンス:
+4.20%
1か月 パフォーマンス:
-5.10%
6か月 パフォーマンス:
+5.30%
1年 パフォーマンス:
-40.64%
1日の値動き範囲:
$2.925
$3.0376
1週間の範囲:
$2.86
$3.1304
52週間の値動き範囲:
$2.225
$5.26
Puma Biotechnology Inc Stock (PBYI) Company Profile
名前
Puma Biotechnology Inc
セクター
電話
(424) 248-6500
住所
10880 WILSHIRE BLVD., LOS ANGELES, CA
PBYI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.98 | 141.89M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-28 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Underperform |
| 2019-10-08 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-10 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-01-17 | 開始されました | Leerink Partners | Mkt Perform |
| 2019-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-11-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-11-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 開始されました | Goldman | Sell |
| 2018-05-11 | 繰り返されました | Stifel | Buy |
| 2017-11-10 | 繰り返されました | Citigroup | Buy |
| 2017-11-10 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 繰り返されました | Stifel | Buy |
| 2017-09-11 | 繰り返されました | Credit Suisse | Outperform |
| 2017-07-10 | 再開されました | Leerink Partners | Outperform |
| 2017-06-06 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 繰り返されました | RBC Capital Mkts | Sector Perform |
すべてを表示
Puma Biotechnology Inc (PBYI) 最新ニュース
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo
Press Release Distribution & PR Platform - ACCESS Newswire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results - BioSpace
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why - MSN
Is The Options Market Predicting A Spike In Puma Biotechnology Stock? - Barchart.com
Is the Options Market Predicting a Spike in Puma Biotechnology Stock? - Yahoo Finance
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential - Seeking Alpha
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Puma Biotech Expands Team: New Hires Receive Strategic Stock Compensation Package - Stock Titan
Further weakness as Puma Biotechnology (NASDAQ:PBYI) drops 11% this week, taking five-year losses to 55% - simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - BioSpace
Groundbreaking Clinical Trial: Neratinib's Novel Combination Approach Targets HER2 Tumors - Stock Titan
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Why Investors Are Buzzing About Puma Biotechnology’s Earnings: Unpacking the Details - procarsrl.com.ar
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now - MSN
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Checking in on Puma Biotechnology Inc (PBYI) after recent insiders movement - Knox Daily
Rhumbline Advisers Lowers Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Armenian Reporter
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.com - Defense World
We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative - Yahoo Finance
Puma Biotech grants stock award to new hire By Investing.com - Investing.com India
Puma Biotechnology, Inc. to Host Earnings Call - ACCESS Newswire
Puma Biotechnology to Present at Barclays 27th Annual Global Healthcare Conference - BioSpace
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - BioSpace
Puma Biotech grants stock award to new hire - Investing.com
Can Puma Biotechnology's Conference Presentation Signal New Growth Opportunities? - StockTitan
Puma Biotechnology’s Earnings Call: Mixed Sentiments and Future Outlook - MSN
Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright - Defense World
Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates - Nasdaq
Puma Biotechnology: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results - sharewise
Puma Biotechnology Reports Strong Earnings Growth in 2024 - TipRanks
Puma Biotech: Q4 Earnings Snapshot - CTPost
Puma Biotechnology: Hold Rating Amidst Flat Sales Growth and Uncertain Drug Prospects - TipRanks
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations By Investing.com - Investing.com South Africa
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc (PBYI) 財務データ
収益
当期純利益
現金流量
EPS
Puma Biotechnology Inc (PBYI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ludwig Jeffrey Jerome | Chief Commercial Officer |
Jan 02 '25 |
Sale |
3.15 |
9,437 |
29,743 |
108,951 |
| HUNT DOUGLAS M | See Remarks |
Jan 02 '25 |
Sale |
3.15 |
8,633 |
27,209 |
124,594 |
| AUERBACH ALAN H | President and CEO |
Jan 02 '25 |
Sale |
3.15 |
33,841 |
106,657 |
7,029,674 |
0.19%
大文字化:
|
ボリューム (24 時間):